Together, the results of this study indicated that afatinib in combination with 7.5 mg/kg of bevacizumab, with adjustable doses and treatment intervals based on the physician’s judgment of the patient’s clinical condition, could be allowed as an effective therapeutic modality for untreated advanced lung adenocarcinoma harboring sensitive EGFR mutations in real-world clinical practice. The gene discussed is EGFR; the disease is lung adenocarcinoma.